Athersys announces Healios enrolled first patient in One-Bridge study in Japan
Athersys announced that its partner, HEALIOS K.K., has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem cell therapy treatment of patients who suffer from acute respiratory distress syndrome. The clinical trial investigates the efficacy and safety of MultiStem therapy for patients with pneumonia-induced ARDS. This trial will enroll 30 patients with 20 subjects receiving the cell therapy treatment and standard of care and 10 subjects receiving standard therapy alone. The primary endpoint will be the number of ventilator-free days - the days in which the patient was not on a ventilator in the 28 days following the treatment.